How Long LL-37 Stays in System — Clearance & Active Life

LL-37 clears your system faster than almost any other research peptide. Peak plasma concentrations occur within 30 to 60 minutes of subcutaneous injection, detectability drops to near-baseline within 12 to 24 hours, and the functional immune cascade. The antimicrobial peptide release, neutrophil recruitment, and cytokine modulation that researchers actually care about. Extends roughly 48 to 72 hours before returning to pre-treatment baseline. That timeline matters because it governs dosing frequency, protocol structure, and outcome consistency in ways most introductory guides skip entirely.

We've worked with research teams structuring LL-37 studies for years. The gap between understanding peptide half-life and understanding therapeutic duration is where most protocols fail.

How long does LL-37 stay in your system after injection?

LL-37 has a plasma half-life of approximately 2 to 4 hours, meaning detectable levels drop rapidly after administration. However, the downstream immune effects. Antimicrobial activity, wound healing signaling, and inflammatory modulation. Persist for 48 to 72 hours as the peptide triggers cascades that outlast its direct presence in circulation. Researchers dosing daily or every 48 hours account for this biological activity window, not just peptide detectability.

Most peptide clearance timelines focus on detection windows. How long a compound remains measurable in plasma or urine. That's not the same as biological duration. LL-37 is enzymatically degraded within hours, but the immune pathways it activates continue functioning long after the peptide itself is undetectable. This article covers the exact pharmacokinetic profile of LL-37, what drives its rapid clearance, how dosing schedules are structured around active duration rather than half-life, and what storage or handling errors shorten functional activity before you even administer the dose.

The Pharmacokinetics of LL-37 — Why It Clears So Rapidly

LL-37 (the active fragment of human cathelicidin antimicrobial peptide hCAP18) is a 37-amino-acid polypeptide that undergoes rapid proteolytic degradation in vivo. Plasma half-life ranges from 2 to 4 hours depending on administration route, subject metabolic state, and concurrent protease activity. Subcutaneous injection. The most common route in research protocols. Produces slower absorption than intravenous administration but still achieves peak plasma concentration within 30 to 60 minutes, followed by exponential decay as serum peptidases cleave the molecule into inactive fragments.

The enzymes responsible for LL-37 degradation include neutrophil elastase, matrix metalloproteinases (MMPs), and cathepsins. All constitutively present in human serum and tissue. These proteases recognize specific cleavage sites within the LL-37 sequence, fragmenting the peptide into shorter, biologically inactive segments. Unlike chemically stable small molecules or pegylated proteins, LL-37 has no structural protection against enzymatic breakdown, which is why detectability windows are so narrow.

But rapid clearance doesn't mean brief activity. LL-37 functions primarily as an immune signaling molecule. Once it binds to formyl peptide receptor-like 1 (FPRL1) on neutrophils, monocytes, and epithelial cells, it triggers intracellular cascades. Calcium mobilization, reactive oxygen species generation, chemokine release. That persist for 48 to 72 hours even after the peptide itself is degraded. Think of LL-37 as the ignition key: it starts the process, but the engine keeps running long after you remove the key.

Research published in the Journal of Immunology demonstrated that neutrophil chemotaxis. One of LL-37's primary immune functions. Remains elevated for up to 72 hours post-exposure in vitro, despite undetectable LL-37 levels in the medium after 6 hours. This disconnect between peptide presence and functional effect is central to understanding how long LL-37 stays active in the system, even when it's no longer detectable.

Biological Activity Duration vs Plasma Half-Life — The Window That Matters

Most researchers make the mistake of equating half-life with therapeutic duration. Half-life tells you how long a compound remains in circulation. Activity duration tells you how long it produces the effect you're studying. For LL-37, those timelines are completely different.

Plasma half-life: 2 to 4 hours. Activity duration: 48 to 72 hours. The mechanism explaining this gap is receptor-mediated signaling amplification. When LL-37 binds FPRL1 receptors, it doesn't just occupy the receptor. It activates a G-protein-coupled cascade that triggers secondary messenger pathways inside the cell. Those pathways. Phospholipase C activation, IP3-mediated calcium release, MAPK phosphorylation. Continue functioning long after LL-37 unbinds and is degraded.

Additionally, LL-37 stimulates the release of cytokines like IL-6, IL-8, and TNF-alpha from immune cells. These cytokines have their own half-lives (6 to 12 hours for IL-8, for example) and propagate the immune response independently. So even when LL-37 is gone, the cytokine environment it created continues driving antimicrobial activity, wound healing, and inflammatory modulation.

In practical terms: if you dose LL-37 at 8 AM on Monday, plasma levels peak by 9 AM and drop below detection by Monday evening. But neutrophil recruitment, antimicrobial peptide expression in epithelial cells, and cytokine-mediated signaling remain elevated through Wednesday morning. That's why most research protocols dose LL-37 daily or every 48 hours. Not three times per day, which the short half-life might otherwise suggest.

Our team has reviewed dosing schedules across hundreds of LL-37 studies. The pattern is consistent: researchers structure protocols around the 48-to-72-hour activity window, not the 2-to-4-hour detection window. Dosing more frequently than every 24 hours shows diminishing returns because the immune pathways are already saturated.

How Administration Route and Dose Affect Clearance Timelines

Subcutaneous injection is the standard route for research-grade LL 37 because it produces sustained absorption and minimizes first-pass degradation. Peak plasma concentration occurs 30 to 60 minutes post-injection, with bioavailability estimated at 60 to 75% compared to intravenous administration. Intramuscular injection produces similar kinetics but slightly faster absorption. Peak levels at 20 to 40 minutes. While oral administration is essentially non-viable due to rapid proteolytic degradation in the gastric and intestinal environment.

Dose magnitude also influences clearance, but not linearly. Doubling the dose doesn't double the activity duration. It increases peak concentration and may extend the detection window by 1 to 2 hours, but the 48-to-72-hour biological activity window remains roughly constant. This is because receptor saturation occurs at relatively low LL-37 concentrations (nanomolar to low micromolar range in tissue), and exceeding that threshold doesn't proportionally amplify downstream signaling.

Research doses in published studies range from 5 mcg/kg to 50 mcg/kg body weight, administered subcutaneously. A 70 kg subject receiving 20 mcg/kg would get 1.4 mg LL-37 per injection. At that dose, plasma half-life is still 2 to 4 hours, but tissue distribution. Particularly to mucosal surfaces, skin, and sites of inflammation. Extends local activity beyond what systemic clearance would predict. LL-37 concentrates at infection or injury sites where protease activity and immune cell density are highest, creating localized reservoirs that sustain antimicrobial effects even as systemic levels drop.

Storage and reconstitution also matter. LL-37 is supplied as lyophilized powder and reconstituted with bacteriostatic water immediately before use. Once reconstituted, the peptide remains stable at 2 to 8°C for up to 28 days, but room temperature storage accelerates degradation. Losing 20 to 30% potency within 72 hours at 25°C. A degraded peptide clears just as fast as an intact one, but it doesn't activate receptors, so the functional activity window collapses to near-zero despite normal pharmacokinetics. Every peptide supplied by Real Peptides undergoes exact amino-acid sequencing and purity verification to ensure the molecule you're administering is structurally intact before it ever reaches your protocol.

LL-37 Clearance & Activity: Dose, Route, and Detection Comparison

The following table compares how administration variables influence both clearance kinetics and biological activity duration. The two timelines that govern protocol structure.

Key takeaway: biological activity outlasts detectability by a factor of 2 to 4× regardless of route. Dosing schedules should target the 48-to-72-hour immune cascade, not the 12-to-24-hour detection window.

What If: LL-37 Clearance Scenarios

What If I Dose LL-37 More Frequently Than Every 24 Hours?

You're unlikely to see proportional benefit increases. Receptor saturation occurs at low nanomolar concentrations, and the immune pathways activated by LL-37. MAPK signaling, calcium mobilization, cytokine transcription. Remain active for 48 to 72 hours. Dosing every 12 hours instead of every 24 doesn't double the antimicrobial effect; it raises peak plasma levels briefly but doesn't extend the biological activity window meaningfully. Most published protocols dose daily or every 48 hours because that aligns with the immune cascade duration, and more frequent administration shows diminishing returns in neutrophil chemotaxis and pathogen clearance assays.

What If Reconstituted LL-37 Is Stored at Room Temperature Overnight?

Expect significant potency loss. Studies on antimicrobial peptide stability show that LL-37 degrades 20 to 30% within 72 hours at 25°C due to spontaneous proteolysis and oxidation of methionine residues. A peptide stored at room temperature for 12 to 24 hours may look identical. Clear, colorless solution. But receptor binding affinity drops as structural integrity degrades. Refrigerate reconstituted LL-37 at 2 to 8°C immediately after mixing, and use within 28 days. Temperature excursions above 8°C accelerate breakdown in ways you can't visually detect.

What If I Need to Detect LL-37 for Compliance or Testing Purposes?

The detection window is narrow: 12 to 24 hours in plasma, possibly up to 36 hours in urine depending on renal clearance rate. Standard immunoassays (ELISA) can detect LL-37 at low nanomolar concentrations, but sensitivity drops rapidly as the peptide is cleaved into fragments. If detection is required for protocol compliance, sample collection should occur within 12 hours of administration. Beyond that, you're measuring background cathelicidin expression, not exogenous LL-37.

What If the Immune Response Seems to Fade Before 48 Hours?

Check peptide integrity first. If reconstituted LL-37 was stored improperly, exposed to freeze-thaw cycles, or left at ambient temperature, potency loss explains shortened activity. Second, consider the biological endpoint: some immune markers (immediate cytokine release) peak within 6 to 12 hours, while others (wound healing, epithelial barrier restoration) take 48 to 72 hours to manifest. If you're measuring early-phase markers only, the apparent fade reflects assay timing, not actual activity loss. Neutrophil recruitment and antimicrobial peptide upregulation in epithelial cells remain elevated well beyond the 24-hour mark in properly dosed subjects.

The Direct Truth About How Long LL-37 Stays in Your System

Here's the honest answer: if you're asking how long LL-37 stays in your system because you're trying to align dosing schedules or avoid overlapping effects, you're focused on the wrong timeline. Plasma clearance is fast. 12 to 24 hours to undetectable. But that's irrelevant to protocol design. What matters is the 48-to-72-hour immune activation window, and that's driven by receptor signaling cascades, not peptide presence.

The short version: LL-37 doesn't work like a small-molecule drug where concentration equals effect. It's an immune trigger. Once it activates FPRL1 receptors and initiates cytokine release, the machinery runs independently. Dosing every 24 to 48 hours captures that window without redundancy. Dosing more frequently wastes peptide. Dosing less frequently creates gaps in immune coverage. The 2-to-4-hour half-life is a pharmacokinetic fact, but it's not a dosing instruction.

Let's be direct about storage, too: peptide degradation before administration is a silent killer of otherwise well-designed protocols. LL-37 doesn't turn cloudy or discolor when it denatures. It just stops working. If your reconstituted vial spent six hours at room temperature during shipping or sat on a lab bench overnight, you're injecting an expensive saline solution, not an active antimicrobial peptide. Every batch of research-grade peptides from Real Peptides is synthesized with exact amino-acid sequencing, third-party purity verification, and cold-chain shipping to ensure what you reconstitute matches what the protocol requires. Functional activity depends on structural integrity, and structural integrity depends on handling from synthesis to injection.

Understanding how long LL-37 stays in your system means distinguishing detection from activity, half-life from therapeutic duration, and peptide presence from immune cascade persistence. Get those distinctions right, and your dosing schedule writes itself. Ignore them, and you end up either overdosing out of caution or underdosing because the peptide 'cleared'. Neither of which reflects what's actually happening at the receptor level. The immune system doesn't care when LL-37 disappeared from plasma. It cares when the signaling stopped, and that's a 48-to-72-hour conversation.